Medicus Pharma: Targeting Urinary Retention with a Novel Non-Invasive Therapy
Medicus Pharma is introducing a groundbreaking therapy to prevent relapse in men suffering from acute urinary retention due to enlarged prostate.
Advancing prostate health with innovation backed by proven biotech pioneers
Every year, nearly 1 million men in the U.S. face the sudden and painful onset of acute urinary retention (AUR)—a medical emergency that often leads to repeat ER visits. Medicus Pharma, known for developing the revolutionary skin cancer patch, is now addressing this urgent need with a non-invasive therapy designed to prevent relapse.
Targeting a $2 billion market, Medicus Pharma’s solution could change how prostate-related emergencies are managed, offering relief and reducing the likelihood of recurrence. With a legacy of biotech innovation and a clear clinical focus, Medicus is advancing a therapy that meets an immediate and recurring need for millions.
For more information on Medicus Pharma (NASDAQ: MDCX) please click on the request investor info button.
Latest Articles
Hot Companies
You might also like
BTV Showcases Contango Ore, Critical Elements Lithium, Dryden Gold, FireFox Gold, Kirkland Lake, Klondike Gold, and Selkirk Mines
This week, BTV - Business Television we feature growth-focused mining companies advancing major projects across North America and Europe. From emerging producers and strategic combinations to high-grade exploration and critical mineral development, this episode highlights the next wave of opportunity in the resource sector, including:
Selkirk Copper: A Yukon restart positioned to deliver new Canadian copper supply by 2028
A 50,000-metre drill program began last summer to expand understanding of the resource and guide updated mine design. The goal is to define a 12–15 year mine life while refreshing permits and engineering.
